Siemens Healthineers will use the technology, which Quanterix acquired as part of its buy of UmanDiagnostics, to develop blood-based Nf-L clinical tests.
The organizations noted in a letter to HHS and FDA that they "believe the agency's actions may in fact inflict greater harm on patients and impede innovation."
The team aims to fully commercialize the 28-biomarker panel for military veterans and civilians who show early symptoms of post-traumatic stress disorder.
This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.
